YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Points Interested in Zevra Therapeutics, Inc.? Here are five stocks we like better. Revenue grew strongly: Zevra's Q2 2026 net revenue rose 53% year over year to $39.7 million, led by MIPLYFFA U.S. revenue of $30.2 million. Adjusted ne…
* Zevra Therapeutics, Inc. press release [https://seekingalpha.com/pr/20608774-zevra-reports-second-quarter-2026-financial-results-and-corporate-update] (ZVRA [https://seekingalpha.com/symbol/ZVRA]): Q2 GAAP EPS of $0.14 beats by $0.03. *…
Ono Pharmaceutical Co. (OPHLF) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurri…
[Stock market activity shows price changes and trading movements in real time] FabrikaCr As the market moves through second-quarter earnings season, investors are paying close attention to small-cap stocks that combine solid profitability…
(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the company's Marketing Authorization Application…
[An arrow pointing downwards on top of a pile of US dollar bills.] * Zevra Therapeutics (ZVRA [https://seekingalpha.com/symbol/ZVRA]) lost ~30% in the premarket on Friday after an expert panel of the EU drug regulator, the European Medicin…
Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access Program BOSTON, July 24, 2026 (GLOBE NEWS…
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announ…
[crash in the market at wall street] franckreporter * Citi has resumed its coverage of Ligand Pharmaceuticals (LGND [https://seekingalpha.com/symbol/LGND]) with a buy rating saying that its acquisition of XOMA Royalty adds a significant nu…
(RTTNews) - Zevra Therapeutics Inc. (ZVRA), a commercial-stage company, on Tuesday announced publication of encouraging Phase 2/3 data for MIPLYFFA in treating Niemann-Pick type C disease in pediatric patients of two years or younger. The…
[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data from…
(RTTNews) - Today's top gainers include Tango Therapeutics, following encouraging pancreatic cancer trial data; Aspire Biopharma, ahead of upcoming milestones; Alvotech, after FDA acceptance of its interchangeable biosimilar to Entyvio for…
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that…
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevr…
Zevra Therapeutics logo Key Points Interested in Zevra Therapeutics, Inc.? Here are five stocks we like better. Strong Q1 financials: Net revenue rose to $36.2 million (up 78% YoY) driven by MIPLYFFA sales and Global EAP reimbursements, an…
Zevra Therapeutics, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Optimization Achieved 78% year-over-year revenue growth driven by MyPlifer's U.S. launch and robust global Expanded Access Program (EAP) reimbu…
Image source: The Motley Fool. DATE May 6, 2026, 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Neil F. McFarlane Chief Commercial Officer — Joshua M. Schafer Chief Financial Officer — Justin Renz Need a quote from a Motley Fool…
In March 2026, GeneDx Holdings Corp. announced a new Niemann-Pick disease type C Sponsored Genetic Testing Program with Zevra Therapeutics, offering no-cost ExomeDx testing to eligible U.S. patients and contributing de-identified results t…
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company h…
GeneDx Holdings Corp. (NASDAQ:WGS) is one of the most promising stocks under $100 to buy. On March 10, GeneDx and Zevra Therapeutics (NASDAQ:ZVRA) announced a new partnership to launch a sponsored genetic testing program for NPC (Niemann-P…
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under…
GeneDx Holdings WGS announced a sponsored genetic testing program with Zevra Therapeutics to improve diagnosis for patients suspected of having Niemann-Pick Disease Type C (NPC), a rare and progressive inherited disorder. The initiative wi…
In March 2026, GeneDx Holdings Corp. announced a Niemann-Pick disease type C sponsored genetic testing program with Zevra Therapeutics, expanding access to ExomeDx at no cost for eligible U.S. patients and contributing de-identified data t…
Zevra Therapeutics(NASDAQ: ZVRA) was one of the healthier companies on the stock exchange on Tuesday. Investors eagerly piled into its shares following the commercial-stage biotech's latest earnings release, leaving Zevra with a slightly o…
Key Points It also posted 44% net revenue growth for the period. Both headline figures crushed the consensus analyst estimates.10 stocks we like better than Zevra Therapeutics › Zevra Therapeutics(NASDAQ: ZVRA) was one of the healthier com…
Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GAITHERSBURG, Md., March 10, 2026--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and…
(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) has reported its fourth quarter and full-year 2025 financial results, marking a sharp turnaround from losses in 2024 as sales of its rare disease therapy MIPLYFFA accelerated. MIPLYFFA (Arimoclom…
Zevra Therapeutics logo Key Points MIPLYFFA-driven profitability: Zevra reported full-year 2025 net revenue of $106.5 million with MIPLYFFA generating $87.4 million, and swung to net income of $83.2 million for 2025 versus a $105.5 million…
Earnings Call Insights: Zevra Therapeutics (ZVRA) Q4 2025 MANAGEMENT VIEW * Neil McFarlane, President and CEO, announced the appointment of Justin Renz as the new Chief Financial Officer, highlighting his "more than 25 years of biopharmace…
* Zevra Therapeutics, Inc. press release [https://seekingalpha.com/pr/20429725-zevra-reports-fourth-quarter-and-full-year-2025-financial-results] (ZVRA [https://seekingalpha.com/symbol/ZVRA]): Q4 GAAP EPS of $0.19 beats by $0.14. * Revenue…
* Zevra Therapeutics, Inc. (ZVRA [https://seekingalpha.com/symbol/ZVRA]) is scheduled to announce Q4 earnings results on Monday, March 9th, after market close. * The consensus EPS Estimate is $0.05 [https://seekingalpha.com/symbol/ZVRA/ear…
(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) announced Thursday the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz brings more than 25 years of financial leadership experience in the biopharmaceutical i…
CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the app…
Stevanato Group (STVN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.2 per share a year ago. These figures are adjusted for non-recurring items.…
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of…
This article first appeared on GuruFocus. With the January 31 submission deadline behind us, the full slate of entries for the 2026 GuruFocus Value Investing Contest is now set. Performance is measured from the January 15, 2026 closing pri…